Success Metrics

Completion Rate
0%(0/1)
Active Trials
2(67%)
Terminated
1(33%)

Phase Distribution

Ph not_applicable
1
33%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution1 total trials
N/ANon-phased studies
1(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Terminated(1)

Detailed Status

Recruiting1
Active, not recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
2
Success Rate
0.0%
Most Advanced
N/A

Trials by Phase

N/A1 (100.0%)

Trials by Status

recruiting133%
active_not_recruiting133%
terminated133%

Recent Activity

2 active trials
Showing 3 of 3
recruiting

Natural History Study for DNA Repair Disorders

NCT05484570
active_not_recruitingnot_applicable

Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer

NCT04653740
terminated

Discovering Cancer Risks From Environmental Contaminants and Maternal/Child Health

NCT05746169

Clinical Trials (3)

Showing 3 of 3 trials
NCT05484570

Natural History Study for DNA Repair Disorders

Recruiting
NCT04653740Not Applicable

Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer

Active Not Recruiting
NCT05746169

Discovering Cancer Risks From Environmental Contaminants and Maternal/Child Health

Terminated

All 3 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
3